Impact of salt on cardiac differential gene expression and coronary lesion in normotensive mineralocorticoid-treated mice

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 302, Issue 9, 2012, Pages

  Wang, Qing ^a,e   Domenighetti, Andrea A ^b   Schäfer, Stephan C ^c   Weber, Johanns ^d   Simon, Alexandra ^a   Maillard, Marc P ^a   Pedrazzini, Thierry ^a   Chen, Ju ^b   Lehr, Hans Anton ^a   Burnier, Michel ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF BERN   (Switzerland)

^d UNIVERSITY OF LAUSANNE   (Switzerland)

^e HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Cardiac gene expression; Cardiac hypertrophy; Deoxycorticosterone acetate

Indexed keywords

COMPLEMENTARY DNA; DEOXYCORTICOSTERONE ACETATE; MINERALOCORTICOID; MYELOID DIFFERENTIATION FACTOR 88; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; RENIN; SODIUM CHLORIDE; TRANSCRIPTION FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; EXTRACELLULAR MATRIX; GENE EXPRESSION; HEART INJURY; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HIGH SODIUM INTAKE; HYPERTENSION; INFLAMMATION; MALE; MOLECULAR MECHANICS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SODIUM INTAKE; SODIUM RESTRICTION; WESTERN BLOTTING;

ANIMALS; CORONARY ARTERY DISEASE; CYTOKINES; DESOXYCORTICOSTERONE; GENE EXPRESSION REGULATION; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MINERALOCORTICOIDS; MYOCARDIUM; PROTEOME; SODIUM CHLORIDE, DIETARY;

EID: 84860527358     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00387.2011     Document Type: Article

References (39)

1. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, Davis AP, Dolinski K, Dwight SS, Eppig JT, Harris MA, Hill DP, Issel-Tarver L, Kasarskis A, Lewis S, Matese JC, Richardson JE, Ringwald M, Rubin GM, Sherlock G. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat Genet 25: 25-29, 2000.
2. Benjamin EJ, Levy D. Why is left ventricular hypertrophy so predictive of morbidity and mortality? Am J Med Sci 317: 168-175, 1999.
3. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium and myocardial fibrosis. J Lab Clin Med 120: 893-901, 1992.
4. Brown NJ. Aldosterone and end-organ damage. Curr Opin Nephrol Hypertens 14: 235-241, 2005.
5. Chapman NR, Perkins ND. Inhibition of the RelA (p65) NF-κB subunit by Egr-1. J Biol Chem 275: 4719-4725, 2000.
6. Chen LF, Greene WC. Shaping the nuclear action of NF-κB. Nat Rev Mol Cell Biol 5: 392-401, 2004.
7. Croquelois A, Domenighetti AA, Nemir M, Lepore M, Rosenblatt-Velin N, Radtke F, Pedrazzini T. Control of the adaptive response of the heart to stress via the Notch1 receptor pathway. J Exp Med 205: 3173-3185, 2008.
8. Devereux RB, Roman MJ. Left ventricular hypertrophy in hypertension: stimuli, patterns, and consequences. Hypertens Res 22: 1-9, 1999.
9. Egan LJ, Mays DC, Huntoon CJ, Bell MP, Pike MG, Sandborn WJ, Lipsky JJ, McKean DJ. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 274: 26448-26453, 1999.
10. Frohlich ED, Apstein C, Chobanian A, Devereux R, Dustan H, Dzau V, Fauad-Tarazi F, Horan MJ, Marcus M, Massie B, Pfeffer MA, Re RN, Roccella EJ, Savage D, Shub C. The heart in hypertension. N Engl J Med 327: 998-1008, 1992.
11. Frohlich ED. Left ventricular hypertrophy: dissociation of structural and functional effects by therapy. Adv Exp Med Biol 308: 175-190, 1991.
12. Garnier A, Bendall JK, Fuchs S, Escoubet B, Rochais F, Hoerter J, Nehme J, Ambroisine ML, De Angelis N, Morineau G, d'Estienne P, Fischmeister R, Heymes C, Pinet F, Delcayre C. Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice. Circulation 110: 1819-1825, 2004.
13. Gu JW, Anand V, Shek EW, Moore MC, Brady AL, Kelly WC, Adair TH. Sodium induces hypertrophy of cultured myocardial myoblasts and vascular smooth muscle cells. Hypertension 3: 1083-1087, 1998.
14. Hosack DA, Dennis G Jr, Sherman BT, Lane HC, Lempicki RA. Identifying biological themes within lists of genes with EASE. Genome Biol 4: R70, 2003.
15. Hummler E, Barker P, Talbot C, Wang Q, Verdumo C, Grubb B, Gatzy J, Burnier M, Horisberger JD, Beermann F, Boucher R, Rossier BC. A mouse model for the renal salt-wasting syndrome pseudohypoaldosteronism. Proc Natl Acad Sci USA 94: 11710-11715, 1997.
16. Kerkela R, Pikkarainen S, Majalahti-Palviainen T, Tokola H, Ruskoaho H. Distinct roles of mitogen-activated protein kinase pathways in GATA-4 transcription factor-mediated regulation of B-type natriuretic peptide gene. J Biol Chem 277: 13752-13760, 2002.
17. Kobayashi N, Mita S, Yoshida K, Honda T, Kobayashi T, Hara K, Nakano S, Tsubokou Y, Matsuoka H. Celiprolol activates eNOS through the PI3K-Akt pathway and inhibits VCAM-1 via NF-κB induced by oxidative stress. Hypertension 42: 1004-1013, 2003.
18. Kohler E, Bertschin S, Woodtli T, Resink T, Erne P. Does aldosteroneinduced cardiac fibrosis involve direct effects on cardiac fibroblasts? J Vasc Res 33: 315-326, 1996.
19. Levy D, Garrison RJ, Savage DD, Kannel DD, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566, 1990.
20. Liebermann DA, Hoffman B. MyD genes in negative growth control. Oncogene 17: 3319-29, 1998.
21. Ma J, Weisberg A, Griffin JP, Vaughan DE, Fogo AB, Brown NJ. Plasminogen activator inhibitor-1 deficiency protects against aldosteroneinduced glomerular injury. Kidney Int 69: 1064-1072, 2006.
22. Murphy AM, Thompson WR, Peng LF, Jones L 2nd. Regulation of the rat cardiac troponin I gene by the transcription factor GATA-4. Biochem J 322: 393-401, 1997.
23. Pikkarainen S, Tokola H, Majalahti-Palviainen T, Kerkela R, Hautala N, Bhalla SS, Charron F, Nemer M, Vuolteenaho O, Ruskoaho H. GATA-4 is a nuclear mediator of mechanical stretch-activated hypertrophic program. J Biol Chem 278: 23807-23816, 2003.
24. Qin W, Rudolph AE, Bond BR, Rocha R, Blomme EA, Goellner JJ, Funder JW, McMahon EG. Transgenic model of aldosterone-driven cardiac hypertrophy and heart failure. Circ Res 93: 69-76, 2003.
25. Rombouts K, Wielant A, Hellemans K, Schuppan D, Geerts A. Influence of aldosterone on collagen synthesis and proliferation of rat cardiac fibroblasts. Br J Pharmacol 134: 224-232, 2001.
26. Saadane N, Alpert L, Chalifour LE. Expression of immediate early genes, GATA-4, and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice. Br J Pharmacol 127: 1165-1176, 1999.
27. Sato A, Saruta T. Aldosterone-induced organ damage: plasma aldosterone level and inappropriate salt status. Hypertens Res 27: 303-310, 2004.
28. Schlaich MP, Kaye DM, Lambert E, Sommerville M, Socratous F, Esler MD. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation 108: 560-565, 2003.
29. Schmieder RE. Dietary salt intake and left ventricular hypertrophy. Nephrol Dial Transplant 12: 245-248, 1997.
30. Thyss R, Virolle V, Imbert V, Peyron JF, Aberdam D, Virolle T. NF-κB/Egr-1/Gadd45 are sequentially activated upon UVB irradiation to mediate epidermal cell death. EMBO J 24: 128-146, 2005.
31. Vermeulen L, De Wilde G, Van Damme P, Vanden Berghe W, Haegeman G. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 22: 1313-1324, 2003.
32. Wang Q, Brunner HR, Burnier M. Determination of cardiac contractility in awake unsedated mice with a fluid-filled catheter. Am J Physiol Heart Circ Physiol 286: H806-H814, 2004.
33. Wang Q, Clement S, Gabbiani G, Horisberger JD, Burnier M, Rossier BC, Hummler E. Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodelling and fibrosis under a normal-salt diet. Am J Physiol Renal Physiol 286: F1178-F1184, 2004.
34. Wang Q, Domenighetti AA, Pedrazzini T, Burnier M. Potassium supplementation reduces cardiac and renal hypertrophy independent of blood pressure in DOCA/salt mice. Hypertension 46: 547-554, 2005.
35. Wang Q, Horisberger JD, Brunner HR, Rossier BC, Burnier M. Saltand angiotensin II-dependent variations in amiloride-sensitive rectal PD in mice. Clin Exp Pharmacol Physiol 27: 60-66, 2000.
36. Wang Q, Hummler E, Nussberger J, Clement S, Gabbiani G, Brunner HR, Burnier M. Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of renin genes. J Am Soc Nephrol 13: 1509-1516, 2002.
37. Young M, Fullerton M, Dilley R, Funder J. Mineralocorticoids, hypertension and cardiac fibrosis. J Clin Invest 93: 2578-2583, 1994.
38. Young M, Head G, Funder JW. Determinants of cardiac fibrosis in experimental hypermineralocorticoid states. Am J Physiol Endocrinol Metab 269: E657-E662, 1995.
39. Yu HC, Burrell LM, Black MJ, Wu LL, Dilley RJ, Cooper ME, Johnston CI. Salt Induces myocardial and renal fibrosis in normotensive and hypertensive rats. Circulation 98: 2621-2628, 1998.